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Molecular imaging (MI) can provide not only structural images using traditional imaging techniques 
but also functional and molecular information using many newly emerging imaging techniques. Over 
the past decade, the utilization of nanotechnology in MI has exhibited many significant advantages 
and provided new opportunities for the imaging of living subjects. It is expected that multimodality 
nanoparticles (NPs) can lead to precise assessment of tumor biology and the tumor microenvironment. 
This review addresses topics related to engineered NPs and summarizes the recent applications of these 
nanoconstructs in cancer optical imaging, ultrasound, photoacoustic imaging, magnetic resonance im-
aging (MRI), and radionuclide imaging. Key challenges involved in the translation of NPs to the clinic are 
discussed.
© 2016 THE AUTHORS. Published by Elsevier LTD on behalf of Chinese Academy of Engineering and 
Higher Education Press Limited Company. This is an open access article under the CC BY-NC-ND 
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1.  Introduction
Cancer is now the leading cause of death in the world [1]. 
China constitutes approximately 20% of the world’s population, 
and comprises 29.42% of new cancer cases and 27% of cancer 
deaths worldwide. In 2012, the cancer incidence rate in China 
was 1.74%, and the cancer mortality rate was 1.22%. In China, 
cancers of the stomach and liver have traditionally occurred 
with the highest frequency; however, the incidence of lung can-
cer has increased as the leading cause of cancer in recent years 
[2]. Despite the fact that huge advances in diagnostic technolo-
gies have led to an explosion of knowledge in cancer research, 
only a minute number of cancer patients are diagnosed at early 
stages due to the poor selectivity and sensitivity of conventional 
diagnostic techniques. 
Traditional imaging technologies reflect mostly anatomical 
changes that differentiate pathological from normal tissue rather 
than measuring the biological processes responsible for disease. 
Molecular imaging (MI) is a rapidly emerging biomedical research 
method that enables visual representation, characterization, and 
quantification of biological processes at the cellular and/or mo-
lecular level within living organisms [3−5]. Several MI modalities 
are currently available, including fluorescence and biolumines-
cence imaging, targeted ultrasound (US), molecular magnetic res-
onance imaging (MRI), magnetic resonance spectroscopy (MRS), 
single-photon-emission computed tomography (SPECT), and 
positron emission tomography (PET). Probes or beacons, which 
can accumulate at the site of interest and allow for imaging, are 
required for MI. However, the limitations of some MI techniques 
include poor spatial resolution, low sensitivity, or poor signal 
penetration through tissues. For example, optical imaging is 
restricted in its depth-penetration capability, leading to poorer 
resolution, whereas MRI can image deep tissues but is much less 
sensitive (Table 1). 
Nanoparticles (NPs) are emerging as a new class of MI agent 
to overcome these major hurdles in detecting human disease. 
NPs have great potential for accurate cancer diagnosis via passive 
accumulation and/or active-targeting approaches [6]. Combining 
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their large payload-carrying capacity, high signal intensity, and 
stability, NPs can deliver high concentrations of imaging agents to 
the target region. NPs are typically smaller than cells [7], and are 
comparable in size to molecules and proteins [8]. 
Historically, many of the developed NPs are considered to 
accumulate in tumors based on the enhanced permeability and 
retention (EPR) effect, which in nanomedicine research has been 
considered a universal feature of solid malignant tumors that 
can serve as the basis for passive tumor-targeting by therapeutic 
and diagnostic NPs [9−17]. The EPR effect was first reported as a 
concept of the delivery of macromolecular drugs to tumors [18]. 
However, the heterogeneity of the EPR effect provoked a debate 
about the real value of this effect. Many experimental scientists, 
pharmacologists, and nanotechnology engineers hold to the 
premise that solid tumors consist of uniform tissue; that is, that 
tumors are homogeneous [19]. However, as this is not the case, 
new strategies such as active targeted NPs have been pursued. 
Targeted NPs can perform with both high sensitivity and specific-
ity to achieve high accumulation at the tumor site [20−23]. Active 
targeting requires the therapeutic agent to be guided to the target 
by conjugating the therapeutic agent or carrier system to a tissue 
or cell-specific ligand. In addition, using targeted NPs with a vari-
ety of moieties to reach multiple binding sites can provide higher 
binding efficiencies for targeting specific tumor sites.
A number of articles review the current applications of na-
notechnologies for MI [24]. This paper presents a brief overview 
of recent developments in nanotechnology for MI, and will also 
address the drawbacks and future challenges of current nanoplat-
forms for the clinical translation of imaging.
2.  Nanoplatforms
A wealth of NP-based systems exploits nanoplatforms for 
many imaging modalities. These NPs come in a wide variety of 
compositions, sizes, shapes, and structures from a variety of 
materials [25,26]. These different materials and shapes range 
from spheres, rods, and cubes to resembling snowflakes, flowers, 
thorns, hemispheres, worms, discoids, and chains—a wide variety 
that enables many imaging modalities (e.g., optical imaging, MRI, 
US, and/or nuclear imaging) for combining disease diagnosis and 
therapy into so-called “theranostic” (therapy plus diagnostic) ap-
plications. As mentioned earlier, NPs have been known to target 
tumors via passive- and/or active-targeting pathways. Due to ab-
normally leaky vasculature and the lack of an effective lymphatic 
drainage system in tumor tissues, NP platforms can passively ac-
cumulate in tumor tissues. These unique phenomena are jointly 
referred to as the EPR effect. Moreover, NPs can recognize, bind 
to, and internalize into tumor cells via receptor-mediated endo-
cytosis when modified with tumor-targeting moieties such as an-
tibodies, nucleic acids, proteins, or other ligands. In this section, 
we will describe exemplary theranostic nanoplatforms along with 
their applications regarding cancer.
2.1.  Optical nanoparticles
Optical imaging offers high sensitivity, cost-effectiveness, 
non-ionizing radiation, and great potential for small-animal stud-
ies. However, the penetration depth of light prohibits deep-tissue 
imaging and is the major disadvantage for in vivo imaging in 
humans; thus, optical imaging is typically not quantitative for 
living-subject imaging studies. An abundance of probes, including 
synthetic fluorophores, semiconductor fluorescent crystals, and 
probes based on lanthanide rare-earth ions, have been developed 
for small-animal imaging [27−29]. 
Quantum dots (QDs) are the most widely studied NPs for pre-
clinical optical imaging applications. Compared with organic fluo-
rophores, QDs possess many superior properties for biological im-
aging, such as a strong resistance to photobleaching and chemical 
degradation, high quantum yields, continuous absorption spectra 
from ultraviolet (UV) to near-infrared (NIR), and large effective 
Stokes shifts [30−33].  Arginine-glycine-aspartic acid (RGD)- 
QDs could selectively bind to luminal endothelium in mouse tu-
mor neovasculature [34]. However, because of their small size, 
QDs demonstrated poor retention inside the tumor, easily wash-
ing back out into the bloodstream [33] (Fig. 1). Nevertheless, the 
major drawbacks for the clinical utility of QDs are their potential 
toxicity and lack of deep-tissue imaging and quantification ability 
[35]. With the help of small-animal PET, radiolabeled QDs were 
found to have rapid uptake into the reticuloendothelial system 
(RES), liver, and spleen [36,37]. In order to reduce the uptake of 
QDs into the RES, human serum albumin (HSA) was explored 
as a coating for QD800-mercaptopropionic acid (MPA) NPs. The 
resulting QD800-MPA-HSA NPs show reduced localization in 
mononuclear phagocytic system-related organs over QD800-
MPA, plausibly due to the low uptake of QD800-MPA-HSA in 
macrophage cells. QD800-MPA-HSA may have great potential for 
in vivo fluorescence imaging [38]. Affibody-modified QDs also 
showed high specificity for targeting human epidermal growth 
factor receptor 2 (HER2)-expressing cells and tumors [39].
Dyes that can be incorporated or encapsulated in polymeric 
NPs include indocyanine green (ICG) [40], NIR region fluorescent 
cyanine 7 (Cy7) [41], and dialkylcarbocyanine fluorophores [42], 
which have been approved by the United States Food and Drug 
Administration (FDA). A nanoplatform strategy is a promising 
method to enable optical imaging to overcome the drawbacks 
of free and small dyes [43,44]. Various nanocarriers have been 
investigated for the delivery of NIR dye to tumor sites, including 
liposomes, silica, polymersomes, and targeted rare-earth nano-
Table 1
Molecular imaging modalities.
Modality Form of energy used Spatial resolution (mm) Advantages Imaging cost Clinical translation
Fluorescence imaging Visible to infrared 
light
< 1 (fluorescence reflectance 
imaging, FRI); 1 (fluorescence 
molecular tomography, FMT)
High sensitivity; multiplexed 
imaging
Low (FRI); medium- 
high (FMT)
Yes
Bioluminescence imaging Visible to infrared 
light
3–5 High sensitivity; high-throughput Low No
Ultrasound (US) High frequency 
sound waves
0.04–0.1 (small-animal US); 
0.1–1 (clinical US)
High sensitivity; portable Low-medium Yes
Positron emission 
tomography (PET)
Annihilation 
photos
1–2 (micro PET); 
6–10 (clinical PET)
High sensitivity; quantitative; 
tracer amount of probe
High Yes
Single-photon-emission 
computed tomography 
(SPECT)
Gamma rays 0.5–2 (micro SPECT); 
7–15 (clinical SPECT)
High sensitivity; quantitative; 
tracer amount of probe
Medium-high Yes
Magnetic resonance imaging 
(MRI)
Radio frequency 
waves
0.01–0.1 (small-animal MRI); 
0.5–1.5 (clinical MRI)
High sensitivity; quantitative; 
tracer amount of probe
High Yes
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crystals [45].
To overcome the light penetration issue and realize deep-tissue 
imaging, radiation-luminescence-excited fluorophores such as QDs 
can be used for in vivo multiplexed optical imaging by mimicking a 
natural bioluminescence resonance energy transfer (BRET) process, 
in which chemical energy is converted into photons to excite the 
QDs [46]. Photocaged upconversion nanoparticles (UCNPs) take ad-
vantage of the photon upconversion of NIR light to UV light to trig-
ger the uncaging of D-luciferin from D-luciferin-conjugated UCNPs. 
The released D-luciferin effectively confers enhanced fluorescence 
and bioluminescence signals in vitro and in vivo, with deep light 
penetration and low cellular damage [47].
Cerenkov luminescence imaging is an emerging imaging mo-
dality, similar to bioluminescence imaging, which captures visible 
photons emitted by Cerenkov radiation [48]. Radioluminescent 
nanophosphors (RLNPs) have been proposed as MI probes in the 
development of combined X-ray/optical imaging modalities, such 
as X-ray luminescence computed tomography (XLCT) [49−51]. PE-
Gylated Eu3+-doped nanophosphors under biological conditions 
were shown to emit luminescence under excitation by either 18F 
radioisotope or X-rays. This capability provides the potential to 
enable novel imaging modalities, such as XLCT or deep-tissue Ce-
renkov luminescence imaging [52].
Raman spectroscopy is based on the light-scattering phenom-
enon, as opposed to the absorption/emission in fluorescence, and 
Raman active molecules are more photostable than fluorophores, 
which are rapidly photobleached. Surface-enhanced Raman spec-
troscopy (SERS), active NPs, and single-wall nanotubes (SWNTs) 
can be used for noninvasive imaging in small living subjects by 
using Raman spectroscopy [53,54]. Affibody-functionalized gold 
silica NPs performed Raman MI of the epidermal growth factor 
receptor in a colon cancer mouse model [55].
Photoacoustic imaging (PAI) is a new hybrid biomedical imag-
ing modality related to optical imaging, which has the potential 
for both functional and anatomic imaging [56]. The generated 
ultrasonic waves are detected by ultrasonic transducers and 
then analyzed to produce images. However, exogenous contrast 
agents are needed for MI, due to the differences in the absorp-
tion spectra of different tissues [57]. Non-plasmonic or plas-
monic NPs, such as gold nanoshells, nanorods, or nanocages, can 
promote light absorption, improving the contrast of PAI signals 
[58]. Perylene-diimide (PDI)-based NIR-absorptive organic NPs 
(micelle-enveloped PDI) are an efficient contrast agent for the PAI 
of deep brain tumors in living mice. By encapsulating them into 
amphiphilic molecules, water-soluble PDI NPs were easily syn-
thesized and exhibited excellent PAI properties [59]. PAI of target-
ed SWNTs may contribute to the noninvasive cancer imaging and 
monitoring of nanotherapeutics in living subjects [60−63]. Mela-
nin nanoparticle (MNP) is another biopolymer with good biocom-
patibility and biodegradability, intrinsic photoacoustic (PA) prop-
erties, and binding ability to drugs, as an efficient endogenous 
nanosystem for imaging-guided chemotherapy [64,65]. Sorafenib 
(SRF) is chosen for constructing PEGylated-melanin-drug system. 
SRF-PEG-MNPs were labeled with 64Cu and used to perform a 
PET/PAI dual modalities imaging-guided therapy [66]. By em-
bedding ultrasmall MNPs into the cavities of apoferritin (APF), 
nanomaterials apoferritin-melanin-Fe (AMF) NPs with core-shell 
structures can easily load 64Cu2+ and Fe3+ to achieve trimodal (PET/
MRI/PAI) imaging [67] (Fig. 2).
2.2.  Ultrasound agents 
US has excellent spatial resolution and contrast sensitivity. 
Due to its low cost and wide availability, US is the most common-
Fig. 1.  (a) Structure and synthesis of QD710-Dendron-RGD2 conjugate. QD710-Dendron with carboxylate terminal group was conjugated with RGD dimer by carbodiim-
ide coupling. In vivo near-infrared fluorescence imaging. The dorsal images of SKOV3 tumor-bearing (arrows) mice (L, left side; R, right side) injected with (b) QD710- 
Dendorn-RGD2 (200 pmol) and (c) QD710-Dendron (200 pmol) at 0.5 h, 1 h, 4 h, 5 h, 5.5 h, 6 h, 8 h, 24 h, and 28 h, respectively. The incidental high fluorescent signals in 
other body parts (arrowheads) might have originated from regular rodent food in stomach and feces in intestine. Adapted with permission from Gao et al. [33], © 2012 
American Chemical Society. 
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ly used clinical imaging modality [68]. Its use is limited in the 
imaging of some organs, such as lungs. Nanoscale US agents have 
been reported in the past decade [69,70]. A strategy to improve 
the in vivo half-life of US agents has been explored by targeting 
vascular markers of tumor angiogenesis [71]. While there have 
been recent examples of nanoscale US agents, due to the short 
in vivo half-life of US agents, the vast majority of targeted agent 
development has focused on seeking vascular markers of tumor 
angiogenesis. Anderson et al. [72] modified the surface of mi-
crobubbles (MBs) with cRGD ligand and then showed that these 
exhibit five-fold higher adhesion to immobilized recombinant 
αvβ3 integrin, compared with control groups. Yan et al. [73] syn-
thesized iRGD-lipopeptides into an MB membrane. The binding 
specificity of iRGD-MBs for endothelial cells was found to be 
significantly stronger than that of control MBs under in vitro 
static and dynamic conditions. Furthermore, many peptides have 
been developed as ligands to direct MBs to integrins. Willmann 
et al. [74] designed MBs with engineered cystine knot (knottin) 
peptides, a new class of targeting ligands to αvβ3 integrin, for tar-
geted contrast-enhanced US imaging of tumor angiogenesis. MB- 
KnottinIntegrin attached significantly more to αvβ3 integrin positive 
cells than to control cells. In addition to integrins, the expression 
of vascular endothelial growth factor receptor 2 (VEGFR2) is an-
other target of interest for imaging and monitoring during treat-
ment. Contrast agent MBs for dual-targeting imaging can be mod-
ified to attach to both VEGFR2 and αvβ3 integrin [75]. As a result of 
the increased avidity that comes from the multi-ligand approach, 
the dual-targeting US MBs exhibited significantly higher signal 
compared with the single-targeting counterparts. 
2.3.  Magnetic nanoparticles
MRI is a noninvasive diagnostic technique providing superb 
image resolution and exquisite soft-tissue contrast for anatomical 
details. A considerable amount of work has been done in the de-
velopment of MRI NPs, and especially with iron oxide NPs (IONPs). 
This is an important class of nanoplatform with the advantages 
of high sensitivity, shortened T1 and T 2 relaxation times in a 
dose-dependent manner, and the versatility to present a wide 
variety of ligands for cellular and molecular imaging. There are 
more than 20 current clinical trials of superparamagnetic iron 
oxide (SPIO) or ultrasmall superparamagnetic iron oxide (USPIO). 
The iron oxide NPs are usually taken up by the RES [76], which 
also permits liver [77–79], spleen [80], and lymph node imaging. 
The accumulation of these NPs at the tumor site is based on the 
EPR effect due to the presence of leaky vasculature as well as up-
take by macrophages.
IONPs such as SPIO NPs have been extensively studied for 
Fig. 2.  (a) Schematic illustration of AMF nanocage synthesis. (b) Representative coronal small animal PET images of HT29 (top) and HepG2 (bottom) tumor-bearing mice 
(n = 4) at 1 h, 2 h, 4 h, 18 h, and 26 h after administration of 64Cu-AMF. White circles indicate tumor location. (c) T1 magnetic resonance images of HT29 (upper) and HepG2 
(lower) tumor model after administration of AMF, red circles indicate the area of tumor. (d) The ultrasound (grey, top), photoacoustic (red, middle) and overlayed coronal 
sections (bottom) of HT29 tumor models before and after tail-vein injection of AMF nanocages. Adapted with permission from Yang et al. [67], © 2015, Elsevier Ltd.
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tumor-targeting probes due to their excellent biocompatibility 
[10]. The synthesis process for these particles ranges from tra-
ditional wet chemistry solution-based methods to more exotic 
techniques [81,82]. The field of magnetic NP probe technology has 
recently been promoted by efforts devoted to developing its po-
tential as an important tool for efficient cross-application MI [83]. 
Hybrid nanotrimers performed dual T1- and T 2-weighted MRI 
with high accuracy and reliability, as revealed by a PET imaging 
study, and displayed favorable biodistribution and suitability for 
in vivo imaging [84] (Fig. 3).
Research with SPIO NPs has already demonstrated their utility 
as an important tool for enhancing magnetic resonance (MR) con-
trast [85]. It is desirable for the NPs used for this application to 
have high magnetization values and a size smaller than 100 nm, 
with a narrow particle-size distribution [86]. Magnetic NPs offer 
a number of advantages, including laser-induced thermal therapy, 
the ability to target specific sites, and relatively low toxicity [87]. 
Biological applications of magnetic NPs also require magnetic 
particles to have a special surface coating that must be nontoxic 
and biocompatible, and that must permit targetable delivery with 
particle localization in a specific area. Such magnetic NPs can be 
easily conjugated to drugs, proteins, enzymes, antibodies, or nu-
cleotides and can be directed to an organ, tissue, or tumor using 
an external magnetic field.
The specific structure of dendrimers makes them an attractive 
NP platform for gadolinium (Gd)-loading due to their narrow size 
distribution (5−10 nm); branched structure, which facilitates the 
presentation of multiple ligands or contrast agents; and associat-
ed renal clearance. For example, Gd-loaded dendrimers targeting 
the folate receptor displayed enhanced MR signal in an animal 
model of a κB-tumor. When designing Gd-based agents, several 
factors need to be considered, since signal intensity at the target 
site is not linearly related to the concentration of the imaging 
moiety. For example, the intracellular accumulation of Gd can 
markedly impact signal intensity. Furthermore, the presence of 
Gd atoms in an NP structure also impacts the efficiency of NP MR 
probes. 
2.4.  Nanoparticles for nuclear imaging
With the development of the micro scanner contributing to 
small-animal imaging, nuclear imaging can be performed with 
low mass amounts to measure the function of biological pro-
cesses [88]. With high contrast sensitivity, PET imaging plays an 
important role in MI, albeit with the disadvantage of low resolu-
tion. Based on existing knowledge of nuclear imaging with small 
molecules, NP-based nuclear imaging agents have been rapidly 
developed. During the past decade, there have been various re-
ports on PET imaging with targeted NPs. The most common way 
to integrate PET imaging capability into NPs is to attach a radio-
metal (e.g., 64Cu) via a metal chelator, such as 1,4,7,10-tetraazacy-
clododecanetetraacetic acid (DOTA) or 1,4,7-triazacyclononane- 
N,N′,N′′-triacetic acid (NOTA). After purification, NPs radiolabeled 
with 64Cu can reach greater than 95% radiochemical purity 
[89−91].
Since no single modality is perfect and sufficient to obtain 
all necessary information, several other NP platforms have been 
investigated for the development of multimodal contrast agents, 
such as for use with combined PET and optical imaging, or PET 
and MRI. Multimodal imaging enables the use of PET for treat-
ment planning with whole-body imaging, and the use of optical 
techniques during therapeutic intervention. Cai et al. [92] de-
veloped a near-infrared fluorescence (NIRF) imaging and PET 
imaging agent based on QD. RGD peptides were modified on the 
Fig. 3.  (a) Engineering the heterogeneous nanostructures for magnetic coupling of T1 and T2 contrast agents (left) and transmission electron microscope (TEM) image of 
dumbbell structure (right). (b) T1- and T2-weighted magnetic resonance images of HT29 tumor bearing mice (n = 3) before and after intravenous injection of Gd-DB-HNTs. 
The left ones show gray scale images, and the right ones show the pseudocolored images. Adapted with permission from Cheng et al. [84], © 2014 American Chemical Society.
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surface of QDs, allowing them to target the αvβ3 integrin. At the 
same time, DOTA was also conjugated for 64Cu labeling. This dual- 
modality probe sufficiently improves tumor contrast while de-
creasing the dose required for in vivo NIRF imaging, thus lead-
ing to a significant reduction in the potential toxicity of QDs 
[93,94]. Similarly, Chen et al. [95] synthesized a 64Cu-DOTA- 
QD-VEGF nanoprobe to primarily target the vasculature through 
a VEGF-VEGFR interaction. Nahrendorf et al. [96,97] synthesized 
a dextran-coated SPIO NP co-labeled with 64Cu and an NIR fluoro-
phore (VivoTag 680), which can perform both fluorescence molec-
ular tomography (FMT) and PET imaging of tumor-associated mac-
rophages. Yang et al. [98] modified a multimodal RGD-targeted 
SPIO. After labeling with 64Cu, the NPs can be used for monitoring 
drug delivery to solid tumors through PET/MR dual-modal imag-
ing [98]. As a photosensitizer, porphyrin not only provides photo-
dynamic ability but also serves as a promising dye for fluorescent 
imaging. Liu et al. [99] developed a 64Cu-porphorysome nano-
platform presenting the ability to detect small bone metastases 
in lower limbs through optical-PET dual-modal imaging. Chen et 
al. [100] recently investigated targeted hollow mesoporous silica 
NPs (HMSNs) for PET/optical imaging of tumor angiogenesis by 
using CD105. They demonstrated a three-fold higher accumula-
tion compared with their non-targeted group [100] (Fig. 4). Liu et 
al. [61] investigated integrin-targeted SWNTs, which performed 
remarkable dual Raman and PET tumor-targeting imaging. Zir-
conium-89 (89Zr) is a new and promising PET radionuclide for 
in vivo studies [101−105]. Ruggiero et al. [106] developed anti-
body-labeled 89Zr-SWNT, which targeted the monomeric vascular 
endothelial-cadherin (VE-cad) epitope with monitoring by PET 
and NIRF imaging. Using this nanoplatform, the tumor angiogen-
esis can be estimated. Lee et al. [107] monodispersely synthesized 
polymer-coated UCNPs and dimeric RGD-conjugated UCNPs. This 
NP platform can be used for optical imaging, MRI, and PET, with 
highly selective targeting to αvβ3 integrin [107]. Lijowski et al. [108] 
designed T1-based αvβ3-targeted 
99mTc-Gd NPs, which produced 
high sensitivity and specific localization of tumor angiogenesis by 
SPECT-MR imaging [108]. Hu et al. [109] investigated 111In-perflu-
orocarbon modified by αvβ3 integrin, producing a multimodal PET-
MR agent. Radiolabeling Ac-Cys-ZEGFR:1907-modified Au-IONP 
(NOTA-Au-IONP-affibody) with PET radionuclide, 64Cu, resulted in 
an epidermal growth factor receptor (EGFR)-targeted PET/optical/
MR imaging probe, 64Cu-NOTA-Au-IONP-affibody, targeted toward 
EGFR-positive tumors [110].
3.  Challenges and future perspectives
Some fundamental hurdles hamper the approval of NPs for 
clinical use; these hurdles correlate to various materials charac-
teristics including size, shape, composition, single crystallinity, 
and magnetism. The first hurdle is that of delivery obstacles. In 
particular, the RES can phagocytose the NPs, rapidly sweeping 
them out of blood circulation and accumulating them in the liver, 
spleen, and bone marrow. This phenomenon gives cause to fur-
ther toxicity concerns. The toxicity of NPs is another very impor-
tant hurdle. Toxicity can result not only from concentration in the 
bone marrow and other organs but also from the composition of 
the NPs themselves, such as the Cd used in QDs and other coat-
ing materials. Additional hurdles include the inability to over-
come certain biological barriers, such as the blood-brain barrier 
(BBB), as well as the lack of control over the distribution of NPs 
following administration. The fate of NPs after their intravenous 
administration is highly variable and dependent on their size, 
morphology, charge, and surface chemistry. An NP size of below 
100 nm is often used in order to increase effectiveness and blood- 
circulation time, for adequate exposure to the tumor and drug 
release. 
Given these existing hurdles, next-generation platforms will 
likely emphasize the development of small-size NPs, their high 
Fig. 4. (a) Surface engineering of HMSN. Uniform dense silica (dSiO2, 1) was firstly synthesized and coated with a shell of MSN, forming dSiO2@MSN (2). Tightly-controlled 
Na2CO3 etching step was introduced to selectively etch dSiO2 away, leaving uniform HMSN (3). As-synthesized HMSN was then surface modified with (3-aminopropyl)tri-
ethoxysilane (APS) to form amino groups conjugated HMSN-NH2 (4) before further bio-conjugations. Anticancer drugs (i.e., doxorubicin, DOX) were then loaded, followed 
by NIR dye (i.e., ZW800) and 64Cu chelator (i.e., NOTA) conjugations, forming NOTA-HMSN(DOX)-ZW800 (5). Afterward, nano-conjugate was PEGylated with SCM-PEG5k-
Mal to render its stability in biological buffers (e.g., phosphate buffered saline, PBS), forming NOTAHMSN(DOX)-ZW800-PEG-Mal (6). Then, thiolated anti-CD105 antibody 
(i.e., TRC105-SH) was conjugated to the NP to obtain NOTAHMSN(DOX)-ZW800-PEG-TRC105 (7). Lastly, PET isotope 64Cu (t
2
1 = 12.7 h) was used to label the NP, forming 64Cu-
NOTAHMSN(DOX)-ZW800-PEG-TRC105 (8). In vivo tumor targeted PET imaging. Serial coronal PET images of 4T1 tumor-bearing mice at different time points post-injec-
tion of (b) targeted group: 64Cu-HMSN-ZW800-TRC105, (c) non-targeted group: 64Cu-HMSN-ZW800, or (d) blocking group: 64Cu-HMSN-ZW800-TRC105 with a blocking 
dose (1 mg per mouse) of free TRC105. Tumors were indicated by yellow arrowheads. Adapted with permission from Chen et al. [100], © 2014 Nature Publishing Group.
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colloidal composition, and bio-stability. Significant improve-
ments in sensitivity and target specificity are expected, which 
will bring huge advancements in current cancer-diagnostic capa-
bilities. Additional regulatory and development considerations 
will arise when future generic nanomedicines are presented for 
health authority (FDA) approval with claims of equivalence to the 
innovator drug. In addition, in the face of the natural biological 
barriers to the delivery of nanomedicines, tissues with aberrant 
pathology, such as tumors, are often very efficient in harnessing 
active biological mechanisms for high nutrient supply and rapid 
growth. Elucidation of these active transport mechanisms and the 
ability to harness them with nanomedicines could provide a step 
forward in the treatment of cancer and other diseases.
4.  Conclusions 
Over the last decade, the field of nanotechnology has experi-
enced tremendous growth and advancement. With substantial 
efforts by both researchers and the biopharmaceutical industry, a 
few nanomedicines have already been successfully approved for 
preclinical and clinical studies. However, the field of nanomed-
icine is still in its early stages due to unfamiliar types of risk in 
safety and efficacy that require further discussion and coopera-
tion among researchers and governmental agencies. The challeng-
es in developing NPs for use in MI may be overcome in the near 
future. 
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